Sunil J Mistry

Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.

H. Watz, A. Lazaar, Sunil J Mistry, 2013, Pulmonary pharmacology & therapeutics.

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

B. Miller, R. Tal-Singer, A. Lazaar, 2015, BMC Pharmacology and Toxicology.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

B. Miller, A. Lazaar, J. Bloomer, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

B. Miller, R. Tal-Singer, A. Lazaar, 2015, BMC Pharmacology and Toxicology.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

B. Miller, A. Lazaar, J. Bloomer, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

R. Tal-Singer, E. Kerem, J. Pilewski, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Insight into the Structural Requirement of 2-Alkyl-4-(biphenylmethoxy)quinolines as Nonpeptide Angiotensin II Receptor Antagonists: A QSAR Approach

V. Vyas, Anurekha Jain, Sunil J Mistry, 2009 .